USA NF Conference
Every year scientists, doctors and health care professionals from many countries come together to share the latest discoveries about neurofibromatosis (NF) and discuss new ways to develop drugs and improve treatment for people living with NF.
2026 conference summary
This June, the Children’s Tumor Foundation convened the 22nd annual NF Conference in Denver, Colorado, bringing together scientists, clinicians, industry partners, and patient advocates from around the world to share the latest research in all forms of neurofibromatosis and schwannomatosis.
This year’s meeting offered an opportunity to reflect on the field’s progress from discovery to impact: how far we have come since the discovery of the genes that cause NF, and how much work remains for patients still waiting for effective treatments.
Meet NF Researchers in Australia
A series of interviews with speakers from the USA NF Conference 2026
Dr Alexandra O’Donohue
Dr O’Donohue is a Postdoctoral Research Fellow in the Bioengineering & Molecular Medicine Laboratory at the University of Sydney.
Dr Yemima Berman
Dr Berman is a Clinical Associate Professor and Head of the Department of Clinical Genetics, including the Neurofibromatosis Clinic at Royal North Shore Hospital in Sydney.
Key findings for patients and carers
Learn about the latest developments without the medical jargon, from a selection of presentations.
Towards treating weak bones in NF1 and preventing tumours in NF2
The information provided below is a combined summary of two presentations by Dr Alexandra O’Donohue at the 2026 NF Conference in the United States.
Understanding routine health surveillance & transition of care in NF1
he information provided below is a combined summary of two presentations at the 2026 NF Conference in the US, selected by Dr Yemima Berman for communication to the NF Community in Australia
Key findings for Health Care Professionals
Dive in to the latest insights and updates with all the important details, from a selection of presentations.
Research aimed at treating porous bones in NF1 & preventing tumours in NF2
The information provided below is a combined summary of two presentations by Dr Alexandra O’Donohue at the 2026 NF Conference in the United States.
The power of routine health surveillance & transition of care in NF1
The information provided below is a combined summary of two presentations at the 2026 NF Conference in the US, selected by Dr Yemima Berman for communication to the NF Community in Australia